INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43m ago
HOUSE PTR2m ago
SEC 13F2m ago
ROBINHOOD CHAIN2m ago
Public company

BIOBIO.BBIO-RAD LABORATORIES, INC.

CIK 0000012208

EDGAR filingsOpen in network
Disclosed transactions57
Buys / sells0 / 2
Max Insider Score36
Connections8with evidence

BIOBIO.B · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
17
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,044 sh
Oct 20, 2026Oct 22, 2026
traded Oct 20, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • ← Insider ofevidence
    Allison SchwartzDirector · Sep 9, 2026
  • ← Insider ofevidence
    Evran SedatEVP, Global Supply Chain · Sep 9, 2026
  • ← Insider ofevidence
    Mehta RajatEVP, GBL Commercial Operations · Sep 9, 2026
  • ← Lobbied forevidence
    FORBES-TATELDA Q2 2026 second quarter · Health issues, Defense, Medicare/Medicaid · Aug 26, 2026
16
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F
$173K
487 sh
Oct 20, 2026
Oct 22, 2026
traded Oct 20, 2026
+2d
SEC FORM 4

Evidence

9
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,044 sh
Oct 20, 2026Oct 22, 2026
traded Oct 20, 2026
+2dSEC FORM 4

Evidence

23
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,027 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

22
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$127K
329 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

23
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
864 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

22
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$107K
277 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

15
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Grant or award
A—
4,026 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

23
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,027 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

27
ES
Evran SedatEVP, Global Supply Chain
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
864 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

19
AS
Allison SchwartzDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
228 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

19
AS
Allison SchwartzDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$32K
82 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

15
AS
Allison SchwartzDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$13K
34 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

15
AS
Allison SchwartzDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Grant or award
A—
719 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

23
AS
Allison SchwartzDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
228 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

27
AS
Allison SchwartzDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
92 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

19
AS
Allison SchwartzDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
92 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

27
MR
Mehta RajatEVP, GBL Commercial Operations
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
456 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

30
MR
Mehta RajatEVP, GBL Commercial Operations
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$90K
233 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

27
MR
Mehta RajatEVP, GBL Commercial Operations
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,370 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

30
MR
Mehta RajatEVP, GBL Commercial Operations
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$195K
504 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

15
MR
Mehta RajatEVP, GBL Commercial Operations
BIOBIO.BBIO-RAD LABORATORIES, INC.
Grant or award
A—
4,601 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

23
MR
Mehta RajatEVP, GBL Commercial Operations
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
456 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

27
MR
Mehta RajatEVP, GBL Commercial Operations
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,370 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

23
EA
Engelhardt Eva AnetteEVP, President, CDG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,027 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

22
EA
Engelhardt Eva AnetteEVP, President, CDG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$142K
369 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

23
EA
Engelhardt Eva AnetteEVP, President, CDG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,152 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

22
EA
Engelhardt Eva AnetteEVP, President, CDG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$187K
485 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

11
EA
Engelhardt Eva AnetteEVP, President, CDG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Grant or award
A—
4,313 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

19
EA
Engelhardt Eva AnetteEVP, President, CDG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,027 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

23
EA
Engelhardt Eva AnetteEVP, President, CDG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,152 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

23
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,027 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

22
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$142K
369 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

23
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,056 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

22
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$181K
470 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

11
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Grant or award
A—
4,313 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

19
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,027 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

23
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
1,056 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

27
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
685 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

26
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$95K
246 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

27
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
768 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

26
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$118K
305 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

15
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Grant or award
A—
2,876 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

27
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
685 sh
Sep 5, 2026Sep 9, 2026
traded Sep 5, 2026
+4dSEC FORM 4

Evidence

27
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
768 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

16
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$59K
154 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

17
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
425 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

5
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
251 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

5
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
174 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

36
EA
Engelhardt Eva AnetteEVP, President, CDG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Open-market sale
SELL$136K
550 sh
May 11, 2026May 13, 2026
traded May 11, 2026
+2dSEC FORM 4

Evidence

17
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
186 sh
Apr 24, 2026Apr 28, 2026
traded Apr 24, 2026
+4dSEC FORM 4

Evidence

13
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Tax withholding
F$22K
77 sh
Apr 24, 2026Apr 28, 2026
traded Apr 24, 2026
+4dSEC FORM 4

Evidence

21
EC
Enloe Courtney CEVP, General Counsel & Sec
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
186 sh
Apr 24, 2026Apr 28, 2026
traded Apr 24, 2026
+4dSEC FORM 4

Evidence

9
PL
Pei Melinda LitherlandDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
407 sh
Apr 21, 2026Apr 23, 2026
traded Apr 21, 2026
+2dSEC FORM 4

Evidence

9
PL
Pei Melinda LitherlandDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Grant or award
A—
369 sh
Apr 21, 2026Apr 23, 2026
traded Apr 21, 2026
+2dSEC FORM 4

Evidence

21
PL
Pei Melinda LitherlandDirector
BIOBIO.BBIO-RAD LABORATORIES, INC.
Option exercise
M—
407 sh
Apr 21, 2026Apr 23, 2026
traded Apr 21, 2026
+2dSEC FORM 4

Evidence

36
BJ
Barry JamesEVP, President, LSG
BIOBIO.BBIO-RAD LABORATORIES, INC.
Open-market sale
SELL$214K
700 sh
Nov 6, 2025Nov 10, 2025
traded Nov 6, 2025
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Engelhardt Eva AnetteEVP, President, CDG · May 13, 2026
  • ← Insider ofevidence
    Enloe Courtney CEVP, General Counsel & Sec · Apr 28, 2026
  • ← Insider ofevidence
    Pei Melinda LitherlandDirector · Apr 23, 2026
  • ← Insider ofevidence
    Barry JamesEVP, President, LSG · Nov 10, 2025

    • Lobbying

    $180K reported · de-duplicated
    2026 Q3 $20K via firms2026 Q2 $80K via firms2026 Q1 $80K via firms
    • FORBES-TATE$20K2026 Q3 · posted Sep 7, 2026 · Medicare/Medicaid, Health issues, Defense
    • FORBES-TATE$80K2026 Q1 · posted Aug 26, 2026 · Health issues, Defense, Medicare/Medicaid
    • FORBES-TATE$80K2026 Q2 · posted Aug 26, 2026 · Health issues, Defense, Medicare/Medicaid

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.

    Source error

    Price history for BIOBIO.B is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.